Hanna N N, Seetharam S, Mauceri H J, Beckett M A, Jaskowiak N T, Salloum R M, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme V P, Kufe D W, Weichselbaum R R
Department of Radiation and Cellular Oncology, University of Chicago, Illinois, USA.
Cancer J. 2000 Sep-Oct;6(5):287-93.
The purpose of this study was to evaluate whether endostatin, an antiangiogenic cleavage fragment of collagen XVIII, enhances the antitumor effects of ionizing radiation (IR). Endostatin was injected to coincide with fractionated radiotherapy.
Xenografts of radioresistant SQ-20B tumor cells were established in athymic nude mice. Lewis lung carcinoma cells were injected into C57BI/6 mice. Mice bearing SQ-20B xenografts were injected intraperitoneally with 2.5 mg/kg/day of murine recombinant endostatin 5 times per week for 2 weeks 3 hours before IR treatment (50 Gy total dose). Mice bearing Lewis lung carcinoma tumors were injected intraperitoneally with endostatin (2.5 mg/kg/day) four times; the first injection was given 24 hours before the first IR dose (15 Gy) and then 3 hours before IR (15 Gy/day) for 3 consecutive days. Microvascular density was assessed on tumor tissue sections by use of CD31 immunohistochemistry and light microscopy. Endothelial cell survival analyses were employed to evaluate endostatin effects on human aortic endothelial cells and human umbilical vein endothelial cells. Endothelial cell apoptosis was examined by use of FACS analysis and DAPI microscopy.
In SQ-20B xenografts, combined treatment with endostatin and IR produced tumor growth inhibition that was most pronounced at the nadir of regression (day 21). By day 35, tumors receiving combined treatment with endostatin and IR were 47% smaller than tumors treated with endostatin alone. Interactive cytotoxic treatment effects between endostatin and IR were also demonstrated in mice bearing Lewis lung carcinoma tumors. Significant tumor growth inhibition was observed in the endostatin/IR group at days 11 and 13 compared with IR alone. Histologic analyses demonstrated a reduction in microvascular density after combined treatment with endostatin and IR compared with endostatin treatment alone. Survival analyses confirmed interactive cytotoxicity between endostatin and IR in both human aortic endothelial cells and human umbilical vein endothelial cells but not in SQ-20B tumor cells. Combined treatment with endostatin and IR produced an increase in cow pulmonary artery endothelial apoptosis compared with either treatment alone.
The tumor regression observed after combined treatment with endostatin and IR suggests additive antitumor effects in both human and murine tumors. Importantly, the concentrations of endostatin employed produced little tumor regression when endostatin was employed as a single agent. The results from the clonogenic and apoptosis assays support the hypothesis that the endothelial compartment is the target for the endostatin/IR interaction.
本研究旨在评估胶原蛋白 XVIII 的抗血管生成裂解片段内皮抑素是否能增强电离辐射(IR)的抗肿瘤效果。在分次放疗期间注射内皮抑素。
在无胸腺裸鼠中建立耐辐射的 SQ - 20B 肿瘤细胞异种移植模型。将 Lewis 肺癌细胞注射到 C57BI/6 小鼠体内。携带 SQ - 20B 异种移植瘤的小鼠在 IR 治疗(总剂量 50 Gy)前 3 小时,每周腹腔注射 5 次,每次 2.5 mg/kg 的鼠重组内皮抑素,共 2 周。携带 Lewis 肺癌肿瘤的小鼠腹腔注射内皮抑素(2.5 mg/kg/天)4 次;第一次注射在第一次 IR 剂量(15 Gy)前 24 小时进行,然后在连续 3 天的 IR(15 Gy/天)前 3 小时进行。通过 CD31 免疫组织化学和光学显微镜评估肿瘤组织切片上的微血管密度。采用内皮细胞存活分析来评估内皮抑素对人主动脉内皮细胞和人脐静脉内皮细胞的作用。通过流式细胞术分析和 DAPI 显微镜检查内皮细胞凋亡情况。
在 SQ - 20B 异种移植瘤中,内皮抑素与 IR 联合治疗产生了肿瘤生长抑制,在消退最低点(第 21 天)最为明显。到第 35 天,接受内皮抑素与 IR 联合治疗的肿瘤比单独接受内皮抑素治疗的肿瘤小 47%。内皮抑素与 IR 之间的交互细胞毒性治疗效果在携带 Lewis 肺癌肿瘤的小鼠中也得到了证实。与单独接受 IR 治疗相比,内皮抑素/IR 组在第 11 天和第 13 天观察到显著的肿瘤生长抑制。组织学分析表明,与单独内皮抑素治疗相比,内皮抑素与 IR 联合治疗后微血管密度降低。存活分析证实了内皮抑素与 IR 在人主动脉内皮细胞和人脐静脉内皮细胞中存在交互细胞毒性,但在 SQ - 20B肿瘤细胞中不存在。与单独任何一种治疗相比,内皮抑素与 IR 联合治疗使牛肺动脉内皮细胞凋亡增加。
内皮抑素与 IR 联合治疗后观察到的肿瘤消退表明在人和鼠肿瘤中都有相加的抗肿瘤作用。重要的是,当内皮抑素作为单一药物使用时,所采用的内皮抑素浓度几乎没有使肿瘤消退。克隆形成和凋亡试验的结果支持内皮抑素/IR 相互作用的靶点是内皮细胞区室这一假说。